Medicenna Therapeutics Corp (MDNA) — Cash Flow-to-Debt Ratio
Medicenna Therapeutics Corp (MDNA) has a Cash Flow-to-Debt Ratio of -0.72x as of December 2025, meaning its operating cash flow of CA$-4.96 Million could theoretically repay -1% of its total liabilities (CA$6.85 Million) in one year. See Medicenna Therapeutics Corp current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medicenna Therapeutics Corp Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Medicenna Therapeutics Corp across 12 annual periods. Also explore net asset momentum of Medicenna Therapeutics Corp to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Medicenna Therapeutics Corp (2014–2025)
Year-by-year debt coverage analysis for Medicenna Therapeutics Corp. For market capitalisation and broader financial context, see MDNA market cap.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.78x | CA$-16.49 Million | CA$9.29 Million | ▼ -52.3% |
| 2024 | -1.17x | CA$-16.26 Million | CA$13.94 Million | ▲ +35.9% |
| 2023 | -1.82x | CA$-12.66 Million | CA$6.96 Million | ▲ +79.8% |
| 2022 | -9.00x | CA$-23.58 Million | CA$2.62 Million | ▼ -141.4% |
| 2021 | -3.73x | CA$-15.31 Million | CA$4.11 Million | ▲ +23.1% |
| 2020 | -4.85x | CA$-8.95 Million | CA$1.85 Million | ▼ -55.1% |
| 2019 | -3.13x | CA$-8.04 Million | CA$2.57 Million | ▲ +31.7% |
| 2018 | -4.58x | CA$-10.12 Million | CA$2.21 Million | ▼ -390.2% |
| 2017 | -0.93x | CA$-7.31 Million | CA$7.83 Million | ▼ -27.4% |
| 2016 | -0.73x | CA$-2.57 Million | CA$3.51 Million | ▲ +75.7% |
| 2015 | -3.02x | CA$-880.32K | CA$291.87K | ▼ -304.1% |
| 2014 | -0.75x | CA$-619.44K | CA$829.89K | — |